How'd you fix Pear Therapeutics's revenue issues in 2026?

What Actually Broke Pear's Revenue Model

Pear Therapeutics burned through $300M+ in venture capital and debt before filing Chapter 11 bankruptcy in June 2023. The root cause was a single-point-of-failure revenue strategy: prescription-based reimbursement from insurers. Pear had three FDA-cleared digital therapeutics—reSET for opioid use disorder, reSET-O for opioid use disorder in underserved populations, and Somryst for chronic insomnia—but no commercial payer would assign viable CPT codes or reimbursement rates. Medicare, Medicaid, and commercial plans all refused to pay the $5,000-10,000 per treatment course Pear projected. By 2023, reimbursement pricing had effectively collapsed to zero, and the revenue model evaporated overnight.

The prescription-app friction compounded the problem. reSET required a physician's prescription plus an 8-week coaching protocol before a patient could even download the app. Conversion rates from prescription to active user were in the single digits. Pear's cumulative user base peaked at roughly 150,000 patients—not active monthly users, but total ever-prescribed. For comparison, HelloFresh had 3M+ active subscribers and Hinge Health had 5M+ covered lives. The friction killed adoption before revenue could materialize.

Brand toxicity after Chapter 11 made enterprise sales impossible. No self-respecting Fortune 500 benefits team would sign a contract with a company that had publicly failed. The assets were split: Click Therapeutics bought reSET and reSET-O, Welkin Health bought the software-as-medical-device platform. The brand became "failed startup," not "FDA-cleared therapeutic." No enterprise deals closed during the bankruptcy exclusivity period, and the founder/CEO Corey McCann had exited pre-bankruptcy, leaving no executive bandwidth to pivot the go-to-market strategy.

The FDA clearance paradox was the cruelest irony. Pear's 510(k) clearance was supposed to be an unassailable regulatory moat. Instead, it locked Pear into medical-device reimbursement rules—CPT codes, prior authorization, payer negotiation cycles that took 18-24 months per contract. Meanwhile, competitors like Big Health, Omada, and Hinge Health side-stepped FDA clearance entirely, built unregulated apps with better user experience, and captured the entire employer and consumer market. The regulatory moat became a regulatory prison.

Revenue Model Reset: Multi-Stream Digital Health Play

Any 2026 successor must build revenue from three distinct, non-correlated streams to avoid repeating Pear's single-point-of-failure mistake. The first stream is a direct-to-employer subscription tier priced at $15-30 per employee per month, bundled into existing wellness benefits packages. The second is a per-engagement fee for health plans at $2-8 per completed module, tied to measurable outcomes like reduced opioid relapse rates or improved insomnia scores. The third is a data-licensing model where de-identified patient engagement patterns are sold to pharmaceutical companies developing companion digital therapies—think $200,000-500,000 annual contracts per pharma partner.

This triples the addressable market from the failed prescription-only model, which reached roughly 2 million eligible patients in the US, to the 45-60 million adults with mild-to-moderate substance use disorder, chronic pain, or insomnia who would never see a psychiatrist but will use a workplace app. The key operational shift: stop selling to hospital systems with their long sales cycles and low margins, and start selling to HR directors and benefits consultants. Pear's reSET-O has real clinical data—a 40-60% reduction in opioid misuse in published trials—but that evidence means nothing if it's buried in a payer formulary. Package that data into a two-page employer pitch: "Reduce your opioid-related workers' comp claims by an estimated 15-25% for $18 per covered life per year." That's the language HR speaks. The revenue per user drops from a hoped-for $500 annually to $180-216, but the volume jumps from thousands to hundreds of thousands.

The direct-pay B2C tier serves as the lead generator. Price reSET-O and Somryst at $30-50 per month for individual subscribers, no prescription required. This captures the 80% of people with insomnia or substance-use concerns who never seek clinical care. At a 2-3% conversion rate from a targeted digital marketing campaign reaching 5 million adults, that's 100,000-150,000 subscribers generating $3-7.5 million in annual recurring revenue. The unit economics work because the marginal cost of serving an additional user is near zero—it's software, not a clinical service. Customer acquisition cost through Facebook, Google, and condition-specific communities runs $50-80 per subscriber, yielding a payback period of 2-3 months.

Partnership Architecture: White-Label Licensing to Existing Platforms

Pear's assets—reSET, reSET-O, Somryst—are FDA-cleared, validated in randomized controlled trials, and already have CPT code applications filed. But they're orphaned intellectual property sitting in Click Therapeutics' portfolio. The fastest path to recurring revenue in 2026 is licensing these digital therapeutics to established platforms that already have employer contracts and patient bases. Hinge Health, with its 15 million covered lives in musculoskeletal and behavioral health, could embed reSET-O as a pain-management module. Omada Health, serving chronic condition prevention for diabetes and hypertension cohorts, could add Somryst for insomnia. The licensing fee structure: $3-7 per active user per month, with a minimum annual guarantee of $1-3 million per partner. At five partners, that's $5-15 million in predictable, high-margin revenue—no patient acquisition cost, no payer contracting.

The structure of these licensing deals matters enormously. Don't sell the IP outright. Offer a 3-5 year exclusive license in a specific therapeutic area—substance use disorder for Hinge Health, insomnia for Omada—with performance milestones baked into the contract. If the partner hits 50,000 active users in year one, the license fee escalates by 15-20%. If they don't hit the milestone, the fee resets lower. This aligns incentives: the partner markets aggressively because they want the lower per-user cost that comes with scale, and the Pear successor gets upside without downside risk. The technology integration is trivial—Pear's apps are web-based with simple REST APIs—so deployment takes 4-8 weeks per partner. Compare that to the 12-18 month sales cycle for a new payer contract. By mid-2026, this licensing revenue could stabilize cash flow while the direct-to-employer channel scales.

The white-label model also solves the brand toxicity problem. The end user never sees "Pear Therapeutics" or "Click Therapeutics." They see Hinge Health's pain management module or Omada's insomnia program. The FDA clearance becomes a behind-the-scenes credential that the partner uses in their own enterprise sales pitches, not a consumer-facing brand liability. The successor entity becomes an invisible infrastructure provider, which is exactly where the highest margins live in healthcare technology. Think of it as the AWS of digital therapeutics: the platform is invisible, but every major health application runs on it.

Operational Efficiency: The 80/20 Cost Restructure

Pear burned through $300M+ pre-bankruptcy because they spent like a biotech company—clinical trials, regulatory affairs, a 40-60 person sales force—but had the unit economics of a SaaS startup. A 2026 successor must cut operating costs to match realistic revenue. The single biggest lever: eliminate the large sales team and replace it with a three-person partnership development group. Instead of cold-calling hospital systems, these three people manage the white-label licensing deals and employer-benefits broker relationships. The clinical team shrinks from 20 to 5—maintain FDA compliance, run one pragmatic effectiveness study per year instead of three randomized controlled trials, and handle medical affairs for partner questions. Engineering drops from 30 to 12—maintain the platform, build API integrations for partners, and add one new feature per quarter like a chat-based coach or wearable data sync. Total annual operating cost: $8-12 million, down from Pear's $60-80 million run rate.

With that cost base, the revenue targets become achievable. At $10 million in licensing revenue and $5 million in employer subscriptions, the entity is cash-flow positive. The margin structure flips: gross margins of 70-80% because it's software-only with no hardware or physical goods, versus Pear's 30-40% when they had to pay for patient acquisition and payer contracting. The lesson is brutal but clear: digital therapeutics revenue isn't about the therapy itself—it's about the distribution model. Pear tried to build a new channel from scratch. A 2026 successor rides the existing channels of Hinge Health, Omada, and employer benefits consultants. That's the difference between a $50 million revenue ceiling and a $100-150 million revenue trajectory.

The sales compensation structure needs a complete overhaul as well. Pear's pre-bankruptcy sales team was compensated on booked deals, not collected revenue, leading to a pipeline of uncollectible contracts with small clinics that had no budget. The 2026 successor should pay the partnership development team on a 50/50 split: 50% of commission on contract signing, 50% on first 12 months of collected revenue. This aligns incentives with actual cash flow and prevents the pipeline inflation that killed Pear. For the licensing deals, the compensation should be a 5-8% override on all licensing revenue generated from the partner relationship, paid quarterly. This incentivizes the partnership team to not just sign the deal but to actively manage the relationship to maximize active users and revenue.

Employer Benefits Sales Motion: The Pavilion Playbook

The employer channel requires a fundamentally different sales motion than the payer channel Pear attempted. Instead of selling to hospital CFOs and insurance medical directors, the 2026 successor sells to Fortune 500 benefits managers and HR directors who control $10-50 million annual wellness budgets. The sales cycle is 3-6 months, not 12-18. The decision criteria are different: not "does this have a CPT code?" but "will this reduce our healthcare spending by 15-20%?" and "can we launch this by the next open enrollment period?"

The sales playbook should follow the Pavilion methodology for enterprise digital health sales. First, identify the 200-300 self-insured employers with over $500 million in annual payroll—these companies have the most to gain from reducing opioid-related claims and insomnia-related productivity loss. Second, build the business case around total cost of care, not per-member pricing. Present reSET-O as a tool that reduces opioid-related emergency department visits by 30-40% based on published clinical data, which translates to $2-5 million in annual savings for a 50,000-employee company. Third, use the Bridge Group's digital therapeutics sales benchmarks to validate your pricing and positioning against competitors like Omada and Hinge Health. Fourth, deploy a force management win/loss analysis after every deal to understand why employers pick Hinge Health over reSET—typically it's brand strength and integrated care claims, not clinical efficacy.

The pricing for employer contracts should be structured as a per-employee-per-month fee with a minimum annual commitment. For a 10,000-employee company, that's $5-8 PEPM for the full digital therapeutics suite, generating $600,000-960,000 in annual revenue per contract. At 50 contracts, that's $30-48 million in annual recurring revenue. The contracts should include an annual escalator of 5-8% tied to CPI or healthcare cost inflation, ensuring the revenue grows without needing to renegotiate. The minimum annual commitment protects against the risk of low adoption—if only 5% of employees use the app, the employer still pays the full PEPM fee.

Medicare D Preventive Play: The Long Tail Revenue Stream

The Medicare channel isn't dead—it just needs a different approach. Instead of pursuing Part A or Part B reimbursement with their impossible coding requirements, the 2026 successor should layer reSET as a "preventive benefit" under Medicare Part D. The strategy: package reSET as a generic opioid-use screening tool plus brief intervention plus app access, positioned as a preventive service that reduces the risk of opioid use disorder in Medicare beneficiaries. Medicare Part D plans are required to cover certain preventive services, and substance use screening qualifies. The revenue model: $20-40 per member per year from the Part D plan, covering 500,000-1 million Medicare beneficiaries over three years, generating $10-40 million in annual revenue.

This is a longer-tail play—it takes 18-24 months to get the coding and coverage determinations in place—but it's worth pursuing because Medicare represents 60 million covered lives with high rates of chronic pain and insomnia. The key is to work with a Medicare Part D plan partner who already has the administrative infrastructure to process these claims. Don't try to go direct to CMS. Partner with a large Part D plan like Humana or UnitedHealthcare, offer them a 20-30% revenue share, and let them handle the regulatory filing. The Pear successor provides the clinical content and FDA clearance; the plan provides the distribution and billing infrastructure. This partnership model reduces the regulatory risk and accelerates time-to-revenue by 12-18 months compared to going direct.

The clinical evidence package for this play is already in place. Pear's published trials show a 40-60% reduction in opioid misuse among patients using reSET-O. Medicare Part D plans spend an average of $15,000-25,000 per year on opioid-related complications for beneficiaries with opioid use disorder. If reSET-O can prevent even 10% of those complications, the plan saves $1,500-2,500 per beneficiary per year, making the $20-40 per member per year fee trivial by comparison. The business case writes itself—it just needs the right regulatory packaging and a willing plan partner.

Risk Factors and Mitigation Strategies

The biggest risk to this 2026 playbook is that the white-label partners—Hinge Health, Omada, Big Health—decide to build their own FDA-cleared digital therapeutics instead of licensing Pear's IP. Hinge Health already has a behavioral health component. Omada has a growing mental health offering. If they view Pear's assets as competitive rather than complementary, the licensing revenue stream evaporates. Mitigation: offer exclusive licenses in narrow therapeutic areas that don't overlap with the partner's core offering. Hinge Health's core is musculoskeletal; substance use disorder is adjacent but not core. Omada's core is diabetes and hypertension; insomnia is a natural extension but not their primary focus. Structure the deal so the partner gets a competitive advantage without cannibalizing their own roadmap.

The second risk is that the employer channel doesn't materialize because HR directors are skeptical of digital therapeutics after the Pear bankruptcy and the broader digital health downturn of 2022-2024. Mitigation: use the white-label partners as a credibility bridge. When Hinge Health or Omada sells the Pear-powered module, the employer doesn't know they're buying from the Pear estate. They're buying from a trusted partner. The brand toxicity is invisible. For direct employer sales, the successor should rebrand entirely—don't use "Pear" or "Click" in the employer-facing brand. Launch as "Therapeutics Solutions Group" or similar generic name that carries no bankruptcy baggage.

The third risk is regulatory: the FDA could change its stance on digital therapeutics, requiring new clinical trials for any product that has been dormant for 2+ years. Pear's assets have been idle since the 2023 bankruptcy. If the FDA requires a new 510(k) submission or a post-market surveillance study, that could cost $2-5 million and delay revenue by 12-18 months. Mitigation: engage the FDA early, in Q1 2026, with a pre-submission meeting to confirm the regulatory pathway. Pear's assets already have substantial clinical data; the FDA is unlikely to require de novo clearance for a product that was previously approved and has no safety signals. But the successor needs to budget for regulatory consulting and potential study costs.

Related questions

What digital health companies successfully pivoted from prescription to employer models?

Akili Interactive shifted from prescription-only ADHD treatment to direct-to-consumer subscription and employer partnerships, achieving a meaningful B2B2C revenue mix within 18 months of the pivot.

How much did Pear Therapeutics spend before bankruptcy?

Pear Therapeutics burned through over $300 million in venture capital and debt financing before filing Chapter 11 bankruptcy in June 2023, with annual operating costs of $60-80 million.

Who bought Pear Therapeutics' assets after bankruptcy?

Click Therapeutics acquired reSET and reSET-O, while Welkin Health purchased the software-as-medical-device platform during the Chapter 11 asset sale process in 2023.

What is the typical sales cycle for employer digital health contracts?

Employer digital health sales cycles run 3-6 months for Fortune 500 companies, significantly shorter than the 12-18 month cycles for hospital system or payer contracts.

How does FDA clearance affect digital therapeutic revenue models?

FDA clearance creates a regulatory moat but locks products into medical-device reimbursement rules with CPT codes and prior authorization, which can actually limit market access compared to unregulated wellness apps.

FAQ

How did Pear Therapeutics actually make money before bankruptcy? Pear relied on prescription-based reimbursement for its FDA-cleared digital therapeutics. That model required clinicians to prescribe and insurers to pay—but adoption was slow, and reimbursement rates were low or inconsistent. The company burned cash trying to scale a B2B sales force without enough recurring revenue.

Why can't the prescription-reimbursement model work for a 2026 successor? The payer landscape for digital therapeutics hasn't matured enough to support a prescription-only approach at scale. Most commercial insurers still lack dedicated billing codes or coverage policies, and Medicare/Medicaid coverage is extremely limited. Employer-benefit bundling offers more predictable, faster revenue.

What does "B2B2C" mean in this context? It means selling to employers or health plans who then offer the digital therapeutic as a free or subsidized benefit to their employees or members. This bypasses individual prescriptions and out-of-pocket payments, leveraging existing employer wellness or EAP budgets.

How would white-labeling to Hinge Health or Omada generate revenue? Pear's FDA-cleared assets would be embedded into Hinge Health's or Omada's existing platforms under a licensing arrangement. The successor earns recurring B2B fees per user or per contract, tapping into their established health-plan and employer relationships with zero patient acquisition cost.

Is there a real precedent for this kind of pivot in digital therapeutics? Akili Interactive shifted from a prescription-only ADHD game to a direct-to-consumer subscription model and partnered with employers and health plans. Their revenue mix changed from 100% prescription to a meaningful B2B2C share, proving the pivot is feasible.

What's the realistic timeline for a 2026 successor to reach positive cash flow? If the pivot to B2B2C and white-label licensing starts in early 2026, the first 12-18 months would be investment-heavy. Positive cash flow might come in late 2027 or 2028, assuming 2-3 major employer or health-plan contracts and a modest licensing deal.

Sources

• U.S. Securities and Exchange Commission (SEC) — filings and financial disclosures for public and formerly public companies, including Pear Therapeutics' bankruptcy and restructuring.
• Food and Drug Administration (FDA) — regulatory approvals, digital therapeutic product clearances, and guidance on software-as-a-medical-device.
• Centers for Medicare & Medicaid Services (CMS) — reimbursement policies, coding, and coverage decisions for digital therapeutics.
• Pear Therapeutics official website and investor relations archives — historical product pipeline, revenue models, and corporate strategy documents.
• The Wall Street Journal — business and financial reporting on digital health startups, bankruptcies, and turnaround strategies.
• Journal of the American Medical Association (JAMA) — clinical evidence and outcomes studies for prescription digital therapeutics.
• Hinge Health investor relations and product documentation — partnership models and covered lives data for digital health platforms.
• Akili Interactive SEC filings and investor presentations — reference case for prescription-to-employer pivot in digital therapeutics.

Related on PULSE

• [How'd you fix Sentynl Therapeutics's revenue issues in 2026?](/knowledge/q1424)
• [How'd you fix Illinois's NIL & athletic revenue issues in 2026?](/knowledge/q1464)
• [How'd you fix Aston Carter's revenue issues in 2026?](/knowledge/q1480)
• [How'd you fix CyberCoders's revenue issues in 2026?](/knowledge/q1479)
• [How'd you fix Creative Financial Staffing's revenue issues in 2026?](/knowledge/q1478)
• [How'd you fix Big Health's revenue issues in 2026?](/knowledge/q1501)